Highest Price Target1
Lowest Price Target1
Consensus Price Target1
Analyst Rating Summary1
Analyst Firms Making Recommendations1
- Cantor Fitzgerald
- Chardan Capital
- Raymond James
- RBC Capital
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Editas Medicine
What is the target price for Editas Medicine (EDIT)?
The latest price target for Editas Medicine (NASDAQ: EDIT) was reported by Cantor Fitzgerald on September 13, 2023. The analyst firm set a price target for $14.00 expecting EDIT to rise to within 12 months (a possible 98.44% upside). 35 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Editas Medicine (EDIT)?
The latest analyst rating for Editas Medicine (NASDAQ: EDIT) was provided by Cantor Fitzgerald, and Editas Medicine reiterated their overweight rating.
When is the next analyst rating going to be posted or updated for Editas Medicine (EDIT)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Editas Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Editas Medicine was filed on September 13, 2023 so you should expect the next rating to be made available sometime around September 13, 2024.
Is the Analyst Rating Editas Medicine (EDIT) correct?
While ratings are subjective and will change, the latest Editas Medicine (EDIT) rating was a reiterated with a price target of $0.00 to $14.00. The current price Editas Medicine (EDIT) is trading at is $7.06, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.